- Home
- LCTX vs FSP Comparison
LCTX vs FSP Comparison
Compare LCTX & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- FSP
- Stock Information
- Founded
- LCTX 1990
- FSP 1981
- Country
- LCTX United States
- FSP United States
- Employees
- LCTX N/A
- FSP N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- FSP Real Estate Investment Trusts
- Sector
- LCTX Health Care
- FSP Real Estate
- Exchange
- LCTX Nasdaq
- FSP Nasdaq
- Market Cap
- LCTX 165.6M
- FSP 160.3M
- IPO Year
- LCTX N/A
- FSP N/A
- Fundamental
- Price
- LCTX $0.88
- FSP $1.72
- Analyst Decision
- LCTX Strong Buy
- FSP
- Analyst Count
- LCTX 3
- FSP 0
- Target Price
- LCTX $5.67
- FSP N/A
- AVG Volume (30 Days)
- LCTX 327.9K
- FSP 270.4K
- Earning Date
- LCTX 11-07-2024
- FSP 11-05-2024
- Dividend Yield
- LCTX N/A
- FSP 2.47%
- EPS Growth
- LCTX N/A
- FSP N/A
- EPS
- LCTX N/A
- FSP N/A
- Revenue
- LCTX $6,186,000.00
- FSP $133,729,000.00
- Revenue This Year
- LCTX N/A
- FSP N/A
- Revenue Next Year
- LCTX $119.00
- FSP $0.02
- P/E Ratio
- LCTX N/A
- FSP N/A
- Revenue Growth
- LCTX N/A
- FSP N/A
- 52 Week Low
- LCTX $0.77
- FSP $1.47
- 52 Week High
- LCTX $1.61
- FSP $2.72
- Technical
- Relative Strength Index (RSI)
- LCTX 47.97
- FSP 53.69
- Support Level
- LCTX $0.83
- FSP $1.70
- Resistance Level
- LCTX $0.94
- FSP $1.70
- Average True Range (ATR)
- LCTX 0.06
- FSP 0.08
- MACD
- LCTX 0.00
- FSP -0.00
- Stochastic Oscillator
- LCTX 40.38
- FSP 50.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.